|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/22/24 Accustem Sciences Inc. 10-K 12/31/23 58:4.8M M2 Compliance LLC/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 1.34M
2: EX-4.4 Instrument Defining the Rights of Security Holders HTML 18K
7: EX-97.1 Clawback Policy re: Recovery of Erroneously HTML 72K
Awarded Compensation
3: EX-31.1 Certification -- §302 - SOA'02 HTML 22K
4: EX-31.2 Certification -- §302 - SOA'02 HTML 21K
5: EX-32.1 Certification -- §906 - SOA'02 HTML 16K
6: EX-32.2 Certification -- §906 - SOA'02 HTML 16K
13: R1 Cover HTML 90K
14: R2 Consolidated Balance Sheets HTML 94K
15: R3 Consolidated Balance Sheets (Parenthetical) HTML 37K
16: R4 Consolidated Statements of Operations HTML 65K
17: R5 Consolidated Statements of Shareholders' Equity HTML 59K
18: R6 Consolidated Statements of Cash Flows HTML 92K
19: R7 Description of Business HTML 25K
20: R8 Summary of Significant Accounting Policies HTML 50K
21: R9 Equipment HTML 25K
22: R10 Accrued Expenses HTML 24K
23: R11 Note Payable HTML 28K
24: R12 License HTML 27K
25: R13 Loss Per Share HTML 36K
26: R14 Share-Based Compensation HTML 148K
27: R15 Related Party Transactions HTML 28K
28: R16 Income Taxes HTML 49K
29: R17 Summary of Significant Accounting Policies HTML 90K
(Policies)
30: R18 Equipment (Tables) HTML 22K
31: R19 Accrued Expenses (Tables) HTML 22K
32: R20 Loss Per Share (Tables) HTML 36K
33: R21 Share-Based Compensation (Tables) HTML 139K
34: R22 Income Taxes (Tables) HTML 44K
35: R23 Description of Business (Details Narrative) HTML 32K
36: R24 Summary of Significant Accounting Policies HTML 23K
(Details Narrative)
37: R25 Schedule of Property and Equipment (Details) HTML 25K
38: R26 Equipment (Details Narrative) HTML 18K
39: R27 Schedule of Accrued Expenses (Details) HTML 24K
40: R28 Note Payable (Details Narrative) HTML 48K
41: R29 License (Details Narrative) HTML 30K
42: R30 Schedule of Loss Per Share (Details) HTML 52K
43: R31 Schedule of Computation of Diluted Net Loss Per HTML 24K
Share (Details)
44: R32 Schedule of Stock Option Activity (Details) HTML 74K
45: R33 Schedule of Stock Valuation Assumptions (Details) HTML 47K
46: R34 Schedule of Warrants Outstanding (Details) HTML 51K
47: R35 Schedule of Warrants Stock Valuation Assumptions HTML 27K
(Details)
48: R36 Share-Based Compensation (Details Narrative) HTML 79K
49: R37 Related Party Transactions (Details Narrative) HTML 39K
50: R38 Schedule of Provision for Income Taxes (Details) HTML 31K
51: R39 Schedule of Income Tax Expenses (Details) HTML 48K
52: R40 Schedule of Deferred Tax Assets and Liabilities HTML 33K
(Details)
53: R41 Income Taxes (Details Narrative) HTML 24K
55: XML IDEA XML File -- Filing Summary XML 92K
58: XML XBRL Instance -- form10-k_htm XML 806K
54: EXCEL IDEA Workbook of Financial Report Info XLSX 81K
9: EX-101.CAL XBRL Calculations -- acut-20231231_cal XML 115K
10: EX-101.DEF XBRL Definitions -- acut-20231231_def XML 284K
11: EX-101.LAB XBRL Labels -- acut-20231231_lab XML 692K
12: EX-101.PRE XBRL Presentations -- acut-20231231_pre XML 521K
8: EX-101.SCH XBRL Schema -- acut-20231231 XSD 85K
56: JSON XBRL Instance as JSON Data -- MetaLinks 308± 449K
57: ZIP XBRL Zipped Folder -- 0001493152-24-010938-xbrl Zip 299K
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of AccuStem Sciences Inc. (the “Company”) on Form 10-K for the year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Keeren Shah, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
Dated: March 22, 2024
| /s/ Keeren Shah | ||
| Name: | Keeren Shah | |
| Title: | Chief Financial Officer |
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 3/22/24 | None on these Dates | ||
| For Period end: | 12/31/23 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/17/22 Accustem Sciences Inc. S-1 66:33M M2 Compliance LLC/FA 12/03/21 Accustem Sciences Inc. 8-K:1,2,3,512/01/21 7:813K M2 Compliance LLC/FA 3/12/21 Accustem Sciences Inc. 20FR12G 8:2.2M Donnelley … Solutions/FA |